• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

With CVS, Bulls Still Have Their Work Cut Out for Them

The company appears to be combating the risk of possible cost-cutting reform with their continued diversification.
By TIMOTHY COLLINS
Sep 12, 2019 | 12:54 PM EDT
Stocks quotes in this article: TWTR, CVS

Today's been an evil case of she loves me, she loves me not. First, Bloomberg reports a White House aide saying an interim deal with China appeared imminent. The market spikes higher. Less than an hour later, a senior administration official says that report is untrue. The market reverses the spike. In between, shorts likely got nailed on the spike, and momentum buyers likely got clipped on the drop. Fair? Unfair? Unfortunately, who cares? This is the market we are in. Headline risk has always existed although social media, especially Twitter (TWTR) , has exacerbated that risk, and this administration has loved to use Twitter to shape its narrative.

The challenge exists in many sectors as well. Healthcare and PBM (Pharmacy Benefit Managers) has faced it with the White House discussing cost-cutting reform. That risk has been a weight on shares of CVS Health (CVS) , but the company appears to be combating that risk with their continued diversification.

Despite the merger with Aetna closing in November 2018, the two companies received "final" approval yesterday after antitrust concerns were dismissed. The move for CVS has been one of concentration risk management as has its foray into medical devices. Where the White House finally lands, if it ever does, on additional reform, CVS management recognized the need to allay some fears. Although the stock is down 2% year-to-date, it is 23% off the lows, so one could argue the strategy is working.

Judging from its recent earnings release last month, the argument strengthens. The company reported earnings per share of $1.89 which exceeded consensus by $0.20. Revenues of $63.4 billion came in roughly $75 million ahead of estimates as well. Based on future guidance, expectations sit around 4% average annual growth on the earnings side. That falls in line with what we've seen over the past five years.

Management guided the full-year earnings from a midpoint of $6.83 to $6.95, but after surpassing Q2 estimates by $0.20 that doesn't exactly scream optimism for Q3/Q4, especially when Q4 is considered one of the stronger, if not strongest quarter, for CVS. The company did raise adjusted operating income by $200 million, so we can conclude the second half of the year will likely see in-line earnings per share on stronger revenue.

The biggest draw for buyers stems in the company's free cash flow. Full-year estimates were raised by $300 million with CVS indicating they would apply this towards debt. The lower interest expense in Q2 helped the big beat which leads me to believe management is being conservative with EPS projections for not only Q3/Q4 but expectations next year.

Despite the big bounce in price recently, bulls still have their work cut out for them. The $68 to $70 area is a big resistance point with $60 acting as support. We're currently sitting dead center of that range with a parabolic support trendline. Above $68 and I'd look for a push to $78. That's my preferred buying trigger. Otherwise, I'd be content to buy between $56.50 and $60 using a scaling in approach to buying starting with a portion at $60, another lot at $58.25, and the final portion at $56.50. The risk-reward buying today is a coin flip, so I'd wait for resistance to be broken or support to be tested.

(CVS Health is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CVS? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Investing | Options | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | Stock of the Day

More from Investing

Rotation Is No Reason to Turn Away from the Markets

James "Rev Shark" DePorre
Jan 21, 2021 4:45 PM EST

Bears may fuss over the routine consolidation combined with rotational action, but here's how I look at the moves.

Jim Cramer: Housing Is Our Bridge

Jim Cramer
Jan 21, 2021 3:59 PM EST

Do not fear the housing sales boom -- this is good news and I'll tell you why.

Cord-Cutting FuboTV and Advertising Platform PubMatic Are Not Buys Here

Bruce Kamich
Jan 21, 2021 2:59 PM EST

Our look at the stocks of both FUBO and PUBM.

Jim Cramer: You Just Won Powerball, Now What?

Jim Cramer
Jan 21, 2021 2:24 PM EST

Remember, you only need to get rich once.

Here's the Beast and Beauty of Investing in Disney Now

Bruce Kamich
Jan 21, 2021 1:54 PM EST

DIS might suffer a pullback in the next several weeks, but longer-term a rally is possible, according to the charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login